Amylin Pharmaceuticals, Inc. Registration Rights AgreementRegistration Rights Agreement • August 14th, 2003 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
Amylin Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the Purchasers (as defined herein) upon the terms set forth in the Purchase Agreement (as defined herein) its 2.25% Convertible Senior Notes due 2008 (the “Securities”). As an inducement to the Purchasers to enter into the Purchase Agreement and in satisfaction of a condition to the obligations of the Purchasers thereunder, the Company agrees with the Purchasers for the benefit of Holders (as defined herein) from time to time of the Registrable Securities (as defined herein) as follows:
DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENTDevice Development and Manufacturing Agreement • August 14th, 2003 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
This DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENT (“Agreement”) is entered into as of July 1, 2003 (the “Effective Date”), by and between Amylin Pharmaceuticals, Inc. (“Amylin”), a corporation organized and existing under the laws of Delaware, and Eli Lilly and Company (“Lilly”), a corporation organized and existing under the laws of the State of Indiana. Amylin and Lilly are sometimes referred to herein individually as a “Party” and collectively as “Parties”. References to “Amylin” and “Lilly” and “Party” or “Parties” shall include their respective Affiliates.
May 20, 2003 Re: Employment Agreement Dear Julia:Employment Agreement • August 14th, 2003 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • California
This letter sets forth the terms and conditions of our agreement (the “Agreement”) regarding your employment with Amylin Pharmaceuticals, Inc. (the “Company”) as of April 15, 2003. You and the Company hereby agree as follows:
ContractAmylin Pharmaceuticals Inc • August 14th, 2003 • Pharmaceutical preparations
THIS NOTE AND ANY COMMON STOCK ISSUABLE UPON THE CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF THIS NOTE IS HEREBY NOTIFIED THAT THE SELLER OF THIS NOTE MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER.
AMYLIN PHARMACEUTICALS, INC. AND ELI LILLY AND COMPANY SECURITY AGREEMENT JUNE 30, 2003Security Agreement • August 14th, 2003 • Amylin Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Security Agreement is made and entered into as of the 30th day of June, 2003 (the “Effective Date”), by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation, having a principal place of business at 9373 Towne Center Drive, San Diego, California 92121 (“Amylin”), and ELI LILLY AND COMPANY, an Indiana corporation having a principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 (“Lilly”). Amylin and Lilly are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
